Highest-materiality recent filing
NextCure Q2 net loss $14.9M; proposes all-stock merger with Avere Therapeutics
Definitive all-stock merger with Avere Therapeutics; combined co to trade as AVRX; concurrent $320M private financing.
NextCure to reverse merge with Avere; Avere holders get ~98% of combined co; $320M PIPE
NextCure (NXTC) to acquire Avere Therapeutics via reverse merger; Avere stockholders will own ~98.11% of combined company; NextCure stockholders ~1.89%.
NextCure Phase 1 SIM0505 data: 55% ORR in gynecologic cancers; cash into Q1 2027
ORR of 55% (11/20) in gynecologic cancers at 4.8-8.0 mg/kg with ≥12 wks follow-up; 52.9% in ovarian, 66.7% in USC.
NextCure reports Q1 net loss $9.8M; cash $29.7M; SIM0505 Fast Track & ASCO data in June
Cash and equivalents $29.7M at March 31, 2026, down $12.1M from year-end; runway into H1 2027 through proof-of-concept for SIM0505.
NextCure reports FY2025 net loss of $55.8M; cash $41.8M; SIM0505 data expected Q2 2026
Cash, cash equivalents and marketable securities at Dec 31, 2025: $41.8M, down from $68.6M a year ago.
NextCure reports $41.8M cash; SIM0505 data Q2 2026, LNCB74 delayed to H2 2026
Preliminary cash, cash equivalents and marketable securities of $41.8M as of Dec 31, 2025; runway into H1 2027.
NextCure enters ATM agreement for up to $14.5M common stock offering with H.C. Wainwright
ATM agreement allows sale of up to $14.5M of common stock at market prices, effective December 19, 2025.
NextCure closes $21.5M PIPE led by Ikarian, Squadron; extends cash runway into H1 2027
Gross proceeds of ~$21.5M from PIPE closed Nov 14, 2025; 708,428 shares at $8.52 and 1,815,049 pre-funded warrants at $8.519.
NextCure Q3 net loss $8.6M; cash $29.1M, PoC data for two ADCs expected H1 2026
Cash $29.1M as of Sep 30, 2025, down from $68.6M; expected to fund operations into mid-2026.
NextCure acquires global rights to CDH6 ADC SIM0505; Q2 net loss $26.8M
Strategic partnership with Simcere Zaiming for SIM0505 (CDH6 ADC); NextCure holds rights ex-China.
NextCure licenses ADC SIM0505 from Simcere Zaiming in deal worth up to $745M
Upfront cash $12M + $5M payable upon financing or by Dec 31, 2025; milestones up to $745M plus tiered royalties up to double digits.
NextCure Q1 net loss narrows to $11.0M; LNCB74 ADC Phase 1 dosing cohort 3
Cash $55.9M as of March 31, 2025, down from $68.6M; expected runway into H2 2026.
NextCure reports FY2024 net loss of $55.7M; cash $68.6M, LNCB74 Phase 1 advancing
Net loss of $55.7M in FY2024 improved from $62.7M in FY2023; R&D expenses $41.5M, G&A $15.7M, both down YoY.
NextCure receives Nasdaq bid price deficiency notice; has until July 30, 2025 to regain compliance
Nasdaq notified NextCure that its closing bid price was below $1.00 for 30 consecutive business days.
NextCure doses first patient in Phase 1 study of B7-H4 ADC LNCB74 for multiple cancers
First patient dosed in Phase 1 study of LNCB74, a B7-H4-targeting ADC.
NextCure FDA accepts IND for ADC LNCB74; Phase 1 trial to start
FDA accepted IND for LNCB74, a B7-H4-targeting antibody-drug conjugate (ADC).
NextCure files IND for product candidate LNCB74
Filed Investigational New Drug application with FDA for LNCB74.
NextCure Q3 net loss $11.5M, cash $75.3M; plans LNCB74 IND by Q4 2024
Net loss of $11.5M for Q3 2024, vs $14.3M in Q3 2023; R&D expense down to $8.8M.
NextCure reports FY2023 net loss $62.7M; workforce cut 37% to extend cash runway to H2 2026
Cash, equivalents, and marketable securities $108.3M at Dec 31, 2023 (down from $159.9M); net loss $62.7M vs $74.7M prior year.
NextCure discontinues NC762, prioritizes LNCB74 ADC; NC410 data expected H1 2024
NC410 (LAIR-2 fusion) combination with pembrolizumab adding patients to 100 mg cohort for microsatellite stable colorectal cancer without liver mets; data expected H1 2024.
NextCure reports Q1 net loss $16.1M, cash $145.5M; pipeline data expected Q4 2023
Net loss $16.1M for Q1 2023 vs $20.6M loss in Q1 2022, narrowing on lower R&D expenses.
NextCure reports FY2022 net loss of $74.7M; cash $159.9M, runway into mid-2025
Net loss of $74.7M for FY2022 vs $69.4M in FY2021, driven by higher R&D expenses.
NextCure discontinues NC318 program; Q3 net loss $18.9M, cash runway extended to mid‑2025
Discontinued NC318 development after no responses in Phase 2 monotherapy; continuing Yale combo trial.
NextCure Q2 net loss $17.9M; cash $185.5M funds ops into Q1 2024
Net loss $17.9M in Q2 2022 vs $18.0M in Q2 2021; no revenue reported.
NextCure reports Q1 2022 net loss of $20.6M; cash at $201.3M, runway into Q1 2024
Net loss of $20.6M vs $16.5M in Q1 2021, driven by higher R&D expenses.
NextCure reports NC318 37% DCR, 5.0 mo median PFS; NC410 safe in Ph1
NC318 Phase 1/2: 37% disease control rate, median PFS 5.0 mo across all tumors; lung cohort 45% DCR, median PFS 5.2 mo.
Dr. Han Myint, M.D. notified NextCure, Inc. (the “Company”) of his plan to retire from his position as Chief Medical Officer of the Company, effective July 1, 2024.
On July 15, 2023, Garry A. Nicholson resigned from the board of directors of NextCure, Inc. (the “Company”), effective August 15, 2023.
elected Anne Borgman, M.D., and Ellen Feigal, M.D., to the Board.
elected Anne Borgman, M.D., and Ellen Feigal, M.D., to the Board.
On September 21, 2021, Dr. Stella Xu notified NextCure, Inc. (the “Company”) of her resignation from the Board of Directors, effective September 30, 2021.
Max materiality 1.00 · Median 0.60 · Most common event earnings